These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38031646)

  • 21. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
    Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
    J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Balzarini J
    Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
    Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
    Galilee M; Alian A
    PLoS Pathog; 2018 Jan; 14(1):e1006849. PubMed ID: 29364950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
    Decha P; Intharathep P; Udommaneethanakit T; Sompornpisut P; Hannongbua S; Wolschann P; Parasuk V
    J Enzyme Inhib Med Chem; 2011 Feb; 26(1):29-36. PubMed ID: 20583854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
    Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
    J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
    Theys K; Camacho RJ; Gomes P; Vandamme AM; Rhee SY;
    Clin Microbiol Infect; 2015 Jun; 21(6):607.e1-8. PubMed ID: 25704446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors.
    Singh AK; Kumar A; Arora S; Kumar R; Verma A; Khalilullah H; Jaremko M; Emwas AH; Kumar P
    Chem Biol Drug Des; 2024 Jan; 103(1):e14372. PubMed ID: 37817296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
    Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
    J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
    Tabassum T; Azeem SM; Muwonge AN; Frey KM
    Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ruxrungtham K; Putcharoen O
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19740. PubMed ID: 25397485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.
    Basson AE; Rhee SY; Parry CM; El-Khatib Z; Charalambous S; De Oliveira T; Pillay D; Hoffmann C; Katzenstein D; Shafer RW; Morris L
    Antimicrob Agents Chemother; 2015 Feb; 59(2):960-71. PubMed ID: 25421485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Penazzato M; Giaquinto C
    Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
    Guo W; Li H; Zhuang D; Jiao L; Liu S; Li L; Liu Y; Gui T; Jia L; Li J
    BMC Infect Dis; 2014 May; 14():237. PubMed ID: 24885612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical uses of non-nucleoside reverse transcriptase inhibitors.
    Harris M; Montaner JS
    Rev Med Virol; 2000; 10(4):217-29. PubMed ID: 10891870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.